SLXN
Silexion Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.35
+0.06%Aug 21, 2026, 00:00 UTC
Silexion Therapeutics Corp received a notice from Nasdaq on August 18, 2026, stating it no longer complies with the minimum shareholders' equity requirement under Rule 5550(b)(1), and the company plans to appeal before the Nasdaq Hearings Panel.
Aug 12, 2026, 00:01 UTC
Silexion Therapeutics Corp. announced the pricing of a public offering of 3,846,161 ordinary shares and series E warrants at a combined price of $0.65 per share, expected to close on August 13, 2026.
Source:Jun 23, 2026, 12:40 UTC
Silexion Therapeutics received approval from Germany's BfArM and a positive ethics committee opinion to initiate a Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer.